Composition for inhibiting reactivation of herpes simplex virus
A composition with live Lacticaseibacillus paracasei YIT 9029 bacteria suppresses herpes simplex virus reactivation, addressing the unclear functionality of lactic acid bacteria in this context and providing a safe, ingestible solution to reduce virus-related symptoms.
Patent Information
- Application Number
- JP2021103189
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-06-22
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2041-06-22
AI Technical Summary
The functionality of lactic acid bacteria in suppressing the reactivation of herpes simplex virus was unclear.
A composition containing live lactic acid bacteria belonging to Bacillus paracasei, specifically Lacticaseibacillus paracasei YIT 9029, is used to suppress the reactivation of herpes simplex virus.
The composition effectively reduces the risk of developing symptoms caused by herpes simplex virus by suppressing its reactivation through the ingestion of live lactic acid bacteria, which can be administered in various forms such as food, drinks, or supplements.
Smart Images

Figure 0007594980000001 
Figure 0007594980000002 
Figure 0007594980000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a composition for inhibiting the reactivation of herpes simplex virus. [Background technology]
[0002] Herpes simplex virus (HSV) is a double-stranded DNA virus belonging to the Herpesviridae family, and there are two subtypes, type 1 (HSV-1) and type 2 (HSV-2). Infections caused by herpes simplex virus include oral herpes, herpes simplex keratitis, and genital herpes. It is generally known that the onset of symptoms caused by herpes simplex virus is due to reactivation of latent virus. That is, while most initial infections during infancy are asymptomatic infections that do not manifest symptoms, the virus that invades the body ascends the nerves and remains latent in the trigeminal ganglion or sacral ganglion for life. The virus is reactivated by a decrease in the immune system of the whole body, and travels up the ascending nerves to return to the periphery, causing symptoms. Antiviral drugs such as acyclovir, valacyclovir, famciclovir, and vidarabine are used for treatment.
[0003] On the other hand, lactic acid bacteria are known to have intestinal regulation and immunoregulatory effects. That is, for example, probiotics (Non-Patent Documents 1, 2), which are defined as "living microorganisms that exert beneficial effects on the host when ingested in appropriate amounts, have been reported to have beneficial effects such as improvement of abdominal symptoms such as constipation and bowel symptoms (Non-Patent Documents 3-5). In addition, for example, Patent Document 1 reveals that heat-treated Lactobacillus johnsonii La1NCC533 is effective for treating or preventing disorders related to the immune system. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E. "Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic." Nature Reviews Gastroenterology & Hepatology (2014) 11: 506-514.
Non-Patent Document 2
Non-Patent Document 3
Non-Patent Document 4
[0005] [Patent Document 1] Special Publication No. 2012-526751 Summary of the Invention [Problem to be solved by the invention]
[0006] Previously, the functionality of lactic acid bacteria in suppressing the reactivation of herpes simplex virus was unclear.
[0007] Therefore, an object of the present invention is to provide a composition for inhibiting the reactivation of herpes simplex virus by utilizing lactic acid bacteria. [Means for solving the problem]
[0008] In order to achieve the above-mentioned object, the inventors have conducted intensive research and discovered that live lactic acid bacteria belonging to Lacticaceae Bacillus paracasei can effectively suppress the reactivation of herpes simplex virus, thereby completing the present invention.
[0009] That is, the present invention provides a composition for inhibiting the reactivation of herpes simplex virus, which contains live lactic acid bacteria belonging to Lacticaceae Bacillus paracasei as an active ingredient.
[0010] In the above composition, the lactic acid bacterium is preferably Lacticaceae Bacillus paracasei YIT 9029 (FERM BP-1366).
[0011] The above composition is preferably used for reducing the risk of developing symptoms caused by herpes simplex virus.
[0012] In the above composition, the lactic acid bacteria is present at a viable cell count of 2×10 per day. 10 It is preferable that the antibody be administered to cells or more.
[0013] The composition is preferably in the form of a food or drink, a medicine, or a supplement.
[0014] On the other hand, from another aspect, the present invention provides an agent for suppressing the reactivation of herpes simplex virus, which comprises live bacteria of lactic acid bacteria belonging to Lacticaceae Bacillus paracasei as an active ingredient.
[0015] On the other hand, from another aspect, the present invention provides use of a live lactic acid bacterium belonging to Lacticaceae Bacillus paracasei for producing a composition for inhibiting reactivation of herpes simplex virus. Effect of the Invention
[0016] According to the present invention, there is provided a composition for inhibiting the reactivation of herpes simplex virus, which contains live lactic acid bacteria belonging to Lacticaceae Bacillus paracasei as an active ingredient. This composition can be easily used as a food, drink, medicine, supplement, or other form that can be ingested on a daily basis by general consumers at their own discretion. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] The composition according to the present invention contains live lactic acid bacteria belonging to Lacticaseibacillus paracasei. The lactic acid bacteria is not particularly limited, but for example, Lacticaseibacillus paracasei YIT 9029 (old classification: Lactobacillus casei YIT 9029) (FERM BP-1366) is preferable. One type of lactic acid bacteria may be used alone, or two or more types may be used in combination. As described in the academic journal published in April 2020 below, the genus of lactic acid bacteria that previously belonged to the Lactobacillus genus has been subdivided, and the genus name of some of the bacterial species has been changed.
[0018] (Reclassification of lactic acid bacteria) ·Zheng et al., “A taxonomic note on the genus Lactobacillus : Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae.” Int. J. Syst. Evol. Microbiol. 2020 Apr; 70(4):2782-2858 DOI 10.1099 / ijsem.0.004107
[0019] In this specification, the lactic acid bacteria will be indicated by the new classification after the reclassification. In addition, among the lactic acid bacteria classified as Lactobacillus casei or Lactobacillus paracasei in the old classification, those that can be newly classified as Lacticaseibacillus paracasei are included in Lacticaseibacillus paracasei in this application.
[0020] The lactic acid bacteria can be grown by a general lactic acid bacteria culture method from a cell-containing material such as a freeze-dried product, frozen or refrigerated product stored in a refrigerator or freezer, or a purchased cell-containing preparation, so that the desired cell count can be appropriately prepared. Examples of media for culturing lactic acid bacteria include, but are not limited to, MRS medium, LBS medium, BCP medium, ILS medium, modified ILS medium, and GAM medium. The lactic acid bacteria can be grown to the desired cell count by applying a small amount of the cells to a flat agar medium containing such a nutrient medium and culturing it statically for 1 to 3 days at a temperature of 25 to 37°C, or adding a small amount of the cells to a liquid medium, suspending the cells, and culturing it statically for 1 to 3 days at a temperature of 25 to 37°C. Examples of the culture form include agitation culture, shaking culture, and neutral culture in addition to static culture. After the cultivation, the cells may be collected by centrifugation or the like to remove the culture medium, or may be suspended in water or the like and washed again by centrifugation or the like, so that the cells are contained in the composition of the present invention. Alternatively, the cells may be contained in the composition of the present invention in the form of the culture medium used for cultivation.
[0021] However, the lactic acid bacteria are used in the form of live bacteria. That is, as shown in the Examples described below, when an individual ingests the lactic acid bacteria and allows them to exist in a living state in the intestine, an increase in IgM antibody in the blood, which is an indicator of reactivation of herpes simplex virus, is suppressed in the individual, and the effect of suppressing reactivation of herpes simplex virus is thereby achieved.
[0022] Here, "viable bacteria" refers to the formation of colonies of the lactic acid bacteria at an optimal temperature, for example, 25°C to 37°C, when a diluted suspension of the bacteria is spread on an agar medium containing an appropriate nutrient medium such as MRS medium. The number of colonies formed can be multiplied by the dilution factor to determine the number of viable bacteria of the lactic acid bacteria contained in the original suspension of the bacteria. The measurement of the viable bacteria number is not limited to the above method, and other commonly used measurement methods such as Mitsuoka's method (Mitsuoka Tomotari, "The World of Intestinal Bacteria," Sobunsha, Tokyo, p53-65) may be used. In the examples described later, the viable bacteria number of a specific lactic acid bacteria in feces was measured by a method in which a sample was treated in advance with propidium monoazide (PMA), which does not allow access to the DNA of viable bacteria, and quantitative PCR was performed, but such a PMA-qPCR method may be used to measure the viable bacteria number.
[0023] The content of the lactic acid bacteria in the composition of the present invention is not particularly limited. For example, the viable cell count of the lactic acid bacteria is 2×10 per 1 g of the total mass of the composition of the present invention in a dry state. 10 cells or more, 2 × 10 10 Cells or more 3×10 11 cells or less, 5 × 10 10 Cells or more 3×10 11 cells or less, 1 × 10 11 Cells or more 3×10 11 The amount of the lactic acid bacteria-containing preparation may be 100 to 2000 cells or less. This allows easy intake of a desired amount per day. In addition, the dosage form of a preparation containing lactic acid bacteria is generally known to be in the form of a liquid preparation, a gel preparation, a freeze-dried preparation, etc., and such a preparation containing lactic acid bacteria may itself constitute the composition containing the lactic acid bacteria according to the present invention.
[0024] The lactic acid bacteria may also be prepared into the form of food and drink, medicine, supplement, etc. together with various food materials and formulation materials, and used as the composition of the present invention. Preparation into such forms can be carried out by known means for the manufacture of food and drink, or known means for the formulation of medicines or supplements.
[0025] Examples of foods and beverages include, but are not limited to, processed meat foods such as ham and sausages, processed seafood foods such as kamaboko and chikuwa, bread, sweets, butter, milk powder, water, fruit juice, milk, soft drinks, tea drinks, and other beverages.
[0026] Further examples of the food and drink include fermented foods and drinks containing the above lactic acid bacteria, such as fermented milk beverages, fermented soy milk beverages, fermented fruit juice beverages, and fermented vegetable juice beverages. In particular, fermented milk beverages are preferred. The above fermented foods and drinks may be produced according to a conventional method, but for example, when producing the above fermented milk foods and drinks, the above lactic acid bacteria are inoculated and cultured in a sterilized milk medium alone or together with other microorganisms, and the resulting mixture is homogenized to obtain a fermented milk base. Next, a separately prepared syrup solution is added and mixed, homogenized with a homogenizer, and flavors are added to complete the final product. The fermented milk foods and drinks thus obtained can be in any form, such as a plain type, soft type, fruit flavor type, solid type, liquid type, etc., that does not contain syrup (sweetener).
[0027] The fermented food and drink products such as the fermented milk beverages may be optionally blended with, for example, sweeteners such as syrup, emulsifiers, thickeners (stabilizers), various vitamins, etc. Examples of sweeteners include sugars such as glucose, sucrose, fructose, fructose glucose liquid sugar, glucose fructose liquid sugar, palatinose, trehalose, lactose, xylose, maltose, honey, and molasses, sugar alcohols such as sorbitol, xylitol, erythritol, lactitol, palatinit, reduced starch syrup, and reduced maltose starch syrup, and high-intensity sweeteners such as aspartame, thaumatin, sucralose, acesulfame K, and stevia. Examples of emulsifiers include sucrose fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, and lecithin. Examples of thickening (stabilizing) agents include agar, gelatin, carrageenan, guar gum, xanthan gum, pectin, locust bean gum, gellan gum, carboxymethylcellulose, soybean polysaccharides, propylene glycol alginate, etc. In addition, vitamins such as vitamin A, vitamin B, vitamin C, vitamin E, etc., minerals such as calcium, magnesium, zinc, iron, manganese, etc., acidulants such as citric acid, lactic acid, acetic acid, malic acid, tartaric acid, gluconic acid, etc., milk fats such as cream, butter, sour cream, etc., flavors such as yogurt, berry, orange, quince, perilla, citrus, apple, mint, grape, apricot, pear, custard cream, peach, melon, banana, tropical, herb, black tea, coffee, etc., herb extract, brown sugar extract, etc. may be blended.
[0028] There is no particular restriction on using commercially available food and drink products as the composition of the present invention. For example, Yakult products such as "New Yakult", "Yakult 1000", and "Yakult 400" are commercially available as beverage products containing the above-mentioned lactic acid bacteria manufactured by Yakult Honsha Co., Ltd., and "Joie", "Soful", "Pretio", and "Yakult Fermented Soy Milk" can be suitably used. In particular, it is more preferable to use Yakult products that contain a large amount of live lactic acid bacteria.
[0029] As pharmaceuticals and supplements, the dosage form of the preparation is not limited, but includes, for example, solid preparations such as tablets, granules, powders, and capsules, liquid preparations such as solutions, suspensions, and emulsions, and freeze-dried preparations. In this case, as necessary, for example, glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glycerides, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid esters, amino acids, gelatin, albumin, water, physiological saline, etc. can be appropriately added as a pharmaceutical carrier. In addition, as necessary, conventional additives such as stabilizers, wetting agents, emulsifiers, binders, isotonicity agents, and excipients can be appropriately added.
[0030] In addition, there is no particular restriction on using commercially available pharmaceuticals and supplements as the composition of the present invention. For example, "Yakult BL Intestinal Regulatory Drug" and "Multi-Probiotic Supplement" are commercially available as products containing the above-mentioned lactic acid bacteria manufactured by Yakult Honsha Co., Ltd., and can be suitably used.
[0031] The composition of the present invention is preferably administered to a subject having the purpose of suppressing the onset of, for example, herpes labialis, herpetic gingivostomatitis, Kaposi's varicelliform eruption, herpes simplex keratitis, genital herpes, etc., which are infectious diseases caused by herpes simplex virus. In addition, it is preferably administered to a subject who is expected to have immunosuppression, for example, a subject who may experience systemic immunosuppression due to surgery, taking immunosuppressants, administering anticancer drugs, radiation exposure, stress, lack of sleep, aging, etc., for a certain period before and after such treatment, in order to suppress the onset of symptoms caused by the above-mentioned virus. That is, in one embodiment, the composition of the present invention may be used to reduce the risk of onset of symptoms caused by herpes simplex virus.
[0032] The administration form of the composition of the present invention is not particularly limited as long as the subject ingests live lactic acid bacteria into the body. However, as shown in the examples below, it is preferable that the ingested lactic acid bacteria reach the intestine alive. Therefore, for example, oral ingestion is preferable. There is no particular limit to the amount of intake. The above lactic acid bacteria should be administered at a concentration of 2×10 per day in terms of bacterial count. 10 The dosage should be 2×10 cells or more per day. 10 Cells or more 3×10 11 cells or less, 5 × 10 10 Cells or more 3×10 11 cells or less, 1 × 10 11 Cells or more 3×10 11 In addition, since the above-mentioned lactic acid bacteria are recognized to be safe even when ingested for a long period of time based on dietary experience, they may be administered for a period of, for example, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, etc. EXAMPLES
[0033] The present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to these examples. In the following, Lacticaceae Bacillus paracasei YIT 9029 (FERM BP-1366) is referred to as "LcS bacteria."
[0034] 1. Subjects The study involved 80 healthy Japanese adults and was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all subjects.
[0035] [2. Primary treatment of feces] The feces collected from the subjects were weighed, and then PBS was added to make the volume 10 times that of the normal sample. φ5.0 mm zirconia beads were added, and the sample was thoroughly suspended for 10 minutes using a multi-sample cell disrupter ("Shake Master", Biomedical Science Co., Ltd.). 200 μL of the fecal suspension was then transferred to a new 2 mL tube. After adding an additional 800 μL of PBS, 800 μL of the supernatant was removed by centrifugation (13,000 × g, 5 minutes), and the sample was stored at -30°C until it was treated with propidium monoazide (PMA).
[0036] 3. Propidium monoazide treatment To measure the number of viable LcS bacteria in collected feces by quantitative PCR, we used propidium monoazide treatment. That is, propidium monoazide (PMA) is a dye that modifies double-stranded DNA, and when irradiated with light of a certain energy and wavelength, the modified DNA is decomposed. Therefore, the PMA-qPCR method, in which the sample is treated with PMA in advance and quantitative PCR is performed, can detect only viable bacteria by utilizing the phenomenon that PMA is impermeable to cell membranes and cannot access the DNA of viable bacteria.
[0037] 2 μL of 5 mM propidium monoazide (PMA) was added to 200 μL of the diluted fecal solution stored at -30°C (final concentration: 50 μM). After vortex mixing, the mixture was left on ice for 5 minutes (protected from light) and then exposed to light for 10 minutes using a light irradiation device (LED Crosslinker, Takara Bio Inc.). The fecal samples after PMA treatment were stored at -30°C until DNA extraction.
[0038] [4. Measurement of viable LcS bacteria count in feces] DNA was extracted from the fecal samples treated with PMA in the above paragraph 3 in the usual manner, and quantitative PCR was performed using the PCR primers shown in the sequences below for specifically detecting LcS bacteria, to calculate the number of LcS bacteria present in 1 g of feces.
[0039] Forward: 5'-CTCAAAGCCGTGACGGTC-3' (SEQ ID NO: 1) Reverse: 5'-ACGTGGTGCTAATAATCCTAGTG-3' (SEQ ID NO: 2)
[0040] 5. Measurement of viral antibody titers The IgG antibody titer against herpes simplex virus type 1 (HSV-1), the specific IgM antibody titer against herpes simplex virus type 1 (HSV-1), the specific IgM antibody titer against varicella-zoster virus (VZV), and the specific IgM antibody titer against cytomegalovirus (CMV) in the serum were analyzed by enzyme-linked immunosorbent assay (ELISA).
[0041] 6. Questionnaire Survey In addition to basic information (gender, age, height, weight), subjects were asked to indicate the number of times per week they consumed dairy products containing LcS bacteria (0-7). In addition, subjects were asked to indicate their medication status during the week prior to the start of the study and when submitting their stool. Subjects who had taken antibiotics, intestinal regulators, or laxatives within the past week were excluded from the analysis.
[0042] [7. Stratified analysis] Based on the results of the questionnaire on lactobacillus intake, subjects who consumed dairy products containing LcS bacteria 6 or more times per week were classified as the high-frequency intake group, and subjects who consumed dairy products containing LcS bacteria 1 to 6 times per week were classified as the low-frequency intake group. Furthermore, the group in which live LcS bacteria were detected by PMA-qPCR was classified as the live LcS detection group, and the group in which live LcS bacteria were not detected (detection limit: 5.9 × 10 5 cells / g) was defined as the non-detection group.
[0043] [8. Statistical analysis] Of the 80 subjects who participated in the study, 72 subjects were analyzed after excluding 4 subjects who met the exclusion criteria (taking antibiotics, intestinal regulators, or laxatives within 1 week prior to stool collection), 3 subjects whose questionnaires were inaccurate, and 1 subject whose number of sequence reads in the gene sequence analysis of 16S rRNA gene amplification products for the separate bacterial flora analysis was less than 10,000, resulting in a total of 72 subjects, consisting of 52 men and 20 women (mean age 38.3 ± 9.0).
[0044] Statistical analysis was performed using unpaired Student's T test or Mann-Whitney U-test between two groups. Data below the detection limit were substituted with half the detection limit.
[0045] [9.Results] The results are summarized in Tables 1 to 3 below.
[0046] [Table 1]
[0047] [Table 2]
[0048] [Table 3]
[0049] As a result, the following became clear: (1) As shown in Table 1, a comparison was made between a group of subjects who frequently consumed dairy products containing live LcS bacteria and a group of subjects who consumed them infrequently. The results showed that the fecal counts of live LcS bacteria in the group who consumed dairy products infrequently were significantly higher than those in the group who consumed them infrequently. (2) As shown in Table 2, a comparison was made between the group of subjects in which live LcS bacteria were detected in their feces and the group in which they were not. The results showed that the test items related to LcS bacteria, such as the number of LcS bacteria ingested, the frequency of ingesting dairy products containing LcS bacteria, and the number of live LcS bacteria in the feces, were significantly higher in the group in which LcS bacteria were detected in the feces than in the group in which they were not. In addition, the antibody titer of herpes simplex virus IgM antibody in the serum was significantly higher in the group in which live LcS bacteria were detected in their feces than in the group in which they were not detected (p value < 0.01). On the other hand, with regard to the antibody titers of herpes simplex virus IgG antibody, varicella zoster virus IgM antibody, and cytomegalovirus IgM antibody in serum, the significance p value for herpes simplex virus IgG antibody was 0.809, the significance p value for varicella zoster virus IgM antibody was 0.353, and the significance p value for cytomegalovirus IgM antibody was 0.661 between the fecal LcS bacteria detection group and the non-detection group, and no significant correlation was observed in any of the cases. (3) Once infected with herpes simplex virus, the virus remains in the body, and herpes simplex virus IgG antibodies are detected in the serum. In order to confirm in more detail that the reactivation of herpes simplex virus is suppressed, the subjects were limited to the IgG antibody detection group, and a comparison was made between the subject group in which live LcS bacteria were detected in the feces and the subject group in which they were not. As a result, as shown in Table 3, it was confirmed that the antibody titer of herpes simplex virus IgM antibodies in the serum tended to be lower in the subject group in which live LcS bacteria were detected in the feces compared to the subject group in which they were not detected, even when the evaluation was limited to the IgG antibody detection group.
[0050] These results suggest that frequent intake of dairy products containing live LcS bacteria significantly increased the number of live LcS bacteria in feces, and that serum IgM antibody titers to herpes simplex virus were significantly suppressed in subjects with live LcS bacteria detected in their feces compared to subjects without live LcS bacteria. In general, a high serum IgM antibody titer to herpes simplex virus is a sign of reactivation of the virus (Luc Letenneur et al. "Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study" PLoS One. 2008;3(11):e3637. doi: 10.1371 / journal.pone.0003637. Epub 2008 Nov 4.). Thus, it is believed that intake of live LcS bacteria can effectively suppress reactivation of herpes simplex virus.
Claims
1. A composition for suppressing reactivation of herpes simplex virus type 1, comprising live bacteria of lactic acid bacteria belonging to Lacticaceae Bacillus paracasei as an active ingredient, wherein the lactic acid bacteria is Lacticaceae Bacillus paracasei YIT 9029 strain having the accession number FERM BP-1366.
2. The composition for inhibiting reactivation of herpes simplex virus type 1 according to claim 1, which is used for reducing the risk of developing symptoms caused by herpes simplex virus type 1.
3. The lactic acid bacteria has a viable cell count of 2×10 per day. 10 3. The composition for inhibiting reactivation of herpes simplex virus type 1 according to claim 1 or 2, which is administered in an amount of 1 to 2 or more cells.
4. The composition for inhibiting reactivation of herpes simplex virus type 1 according to any one of claims 1 to 3, which is in the form of a food or drink, a medicine, or a supplement.
5. A reactivation inhibitor for herpes simplex virus type 1, comprising as an active ingredient live bacteria of lactic acid bacteria belonging to Lacticaceae Bacillus paracasei, said agent being Lacticaceae Bacillus paracasei YIT 9029 strain having the accession number FERM BP-1366.
6. 1. Use of live lactic acid bacteria belonging to Lacticaceae Bacillus paracasei for the manufacture of a composition for inhibiting reactivation of herpes simplex virus type 1, wherein the lactic acid bacteria is Lacticaceae Bacillus paracasei YIT 9029 strain having the accession number FERM BP-1366.
Citation Information
Patent Citations
Interleukin-15 production promoter, prophylactic / therapeutic agent and food / Beverage for digestive organ disorder
JP2002241292A
Use of Lactic Acid Bacteria for Treatment of Viral Infections
JP2009511470A
Lactobacillus johnsonii La1NCC533 (CNCMI-1225) and immunodeficiency
JP2012526751A
Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
WO2012101500A1
Probiotics for producing antiviral factors
WO2014038929A1
